CEO Update – March 2019
THE GREATEST BREAKTHROUGH IN 30 YEARS FOR THE TREATMENT OF TREATMENT RESISTANT DEPRESSION IS SPRAVATO / ESKETAMINE! Is it really? Or are they just confirming what we have known for the last eight years? Yes, finally Johnson and Johnson has successfully received FDA approval to provide the medical community with a new ketamine metabolite …